CCDC85A

Across TCGA pan-cancer cohorts, CCDC85A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of CCDC85A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CCDC85A RNA is repressed in tumor relative to normal tissue. In most cancer types CCDC85A is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, LUAD, and LUSC are the cancer types where CCDC85A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC85A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−2.277	<.001	11	view →
LUAD	Female	III,IV	−2.320	<.001	9	view →
LUSC	Female	II,III,IV	−2.391	<.001	8	view →
UCEC	All	All	−1.317	<.001	8	view →
KIRC	All	All	+0.569	<.001	8	view →
COAD	Male	II,III,IV	−0.376	<.001	7	view →
LIHC	All	All	+0.191	<.001	7	view →
BRCA	All	III,IV	−1.296	<.001	6	view →
BLCA	All	IV	−0.457	.011	4	view →
READ	Female	All	−0.802	<.001	2	view →
PRAD	All	All	−0.688	<.001	2	view →
KIRP	Male	All	−0.391	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

CCDC85A–THCA

Open the THCA breakdown →